The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines

Kathleen O'Connell, Maria Prencipe, Amanda O'Neill, Claire Corcoran, Sweta Rani, Michael Henry, Paul Dowling, Paula Meleady, Lorraine O'Driscoll, William Watson, Robert O'Connor

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Docetaxel is a taxane-derived chemotherapy drug that has been approved for treatment of prostate cancer. While docetaxel is frequently used as a treatment for hormone-refractory prostate cancer, a subset of patients either do not respond to this treatment or those that do respond eventually become resistant to the drug over time. Resistance to docetaxel is complex and multi-factoral and further understanding of the cellular biochemistry underlying resistance is vital to improve treatment efficacy. To identify proteins altered in the resistant phenotype, three parental cell lines DU145, 22RV1 and PC-3, as well as their docetaxel resistant sub-lines, were subjected to quantitative label-free LC-MS proteomic profiling. A total of 189 significant (p < 0.05) protein abundance changes were identified in the DU145 resistant sub-lines, 254 in the 22RV1 sub-lines, and 51 and 72 in the 8 and 12 nM resistant PC-3 sub-lines, respectively. From these, 29 proteins demonstrated a significant (p < 0.05) fold change across two or more resistant variants. These included proteins indicative of an epithelial-to-mesenchemyl transition as well as altered heat shock response elements.

Original languageEnglish
Pages (from-to)2115-2126
Number of pages12
JournalProteomics
Volume12
Issue number13
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Keywords

  • Cancer
  • Cell biology
  • Docetaxel
  • Prostate
  • Resistant

Fingerprint

Dive into the research topics of 'The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines'. Together they form a unique fingerprint.

Cite this